Interpretation of a new biomarker for the right ventricle introduced to evaluate the severity of pulmonary arterial hypertension

Assessment of right ventricular (RV) performance can be a challenge for clinicians and researchers, especially in the diseased heart. In their study on pulmonary arterial hypertension (PAH) in pediatric patients, Yang et al. sought to identify a quantitative measure to predict disease progression and to assist treatment planning.1 The authors defined a potential biomarker (based on MRI and right heart catheterization data) that appears to correlate with clinical worsening, and outperforms several other metrics studied. During follow-up for a period from 1 to 10 years since diagnosis, an upward trend of the new biomarker was found for patients with clinical worsening (N = 8) compared with a well-defined stable subgroup (N = 9).

Read the full article online

Topics

Biomarkers
Pediatric
Pulmonary Arterial Hypertension
Right Ventricle: Structure, Function and Dysfunction

Authors

Peter L.M. Kerkhof, John K-J. Li, Neal Handly

Published in:

Pulmonary Circulation Vol 9: No 2 cover image

June 2019

Pulmonary Circulation Vol 9: No 2

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg